WALTHAM,
Mass., Feb. 26, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a
development-stage biotechnology company advancing best-in-class
antibody engineering, rational therapeutic combinations, and
precision medicine approaches for the treatment of Inflammatory
Bowel Disease ("IBD"), today announced that management will
participate in the TD Cowen 44th Annual Health Care
Conference.
Cameron Turtle, Chief Executive
Officer, will participate in the Inflammation & Immunology
Corporate Panel Discussion on Tuesday, March
5, 2024, at 2:10 p.m. Eastern
time.
To access this webcast, please visit the "Events &
Presentations" page within the Investors section of the Spyre
website at ir.spyre.com. An archive of the webcast will be
available for replay for 30 days following the end of the
conference.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to
create next-generation inflammatory bowel disease (IBD) products by
combining best-in-class antibody engineering, rational therapeutic
combinations, and precision medicine approaches. Spyre's pipeline
includes extended half-life antibodies targeting α4β7, TL1A, and
IL-23. For more information, visit Spyre's website at
www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and
LinkedIn
For Investors :
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com
For Media :
Peg Rusconi
Peg.rusconi@vergescientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-the-44th-annual-td-cowen-health-care-conference-302068561.html
SOURCE Spyre Therapeutics, Inc.